{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-396065","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2026-09-21T11:10:39+00:00","discovered_at":"2026-09-21T11:15:00.609931+00:00","generated_at":"2026-09-21T11:15:19.040992+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Alkermes ALKS 7290 shows positive Phase 1b ADHD data; AISRS cuts 14–19 pts","bullets":["ALKS 7290 (OX2R agonist) improved ADHD symptoms: median AISRS reductions of 14.0 (20 mg) and 19.0 (50 mg) at day 14.","CGI-S median reductions of 1.0 (20 mg) and 2.0 (50 mg) at day 14; shift from markedly/moderately ill to mildly ill.","Generally well tolerated; no serious TEAEs; most common mild events: insomnia, pollakiuria, dizziness, change in sustained attention.","Phase 2 study (NCT07755410) enrolling ~312 adults with ADHD; first dose Sept 2026; data expected 2027.","First orexin 2 receptor agonist to show clinically meaningful ADHD improvements; supports broader orexin portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-396065","json":"https://secwatch.observer/filing/0001193125-26-396065.json","markdown":"https://secwatch.observer/filing/0001193125-26-396065.md","text":"https://secwatch.observer/filing/0001193125-26-396065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/0001193125-26-396065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/alks-20260921.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-21T11:15:19.040992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}